Abstract:Objective: To describe the clinical features of neuromyelitis optica spectrum disorder (NMOSD) through patient registry in Yangtze River Delta area of China. Methods: A total of 502 consecutive patients diagnosed with aquaporin-4 antibody (AQP4-ab)-positive NMOSD were registered between December 2018 to January 2021 in multiple tertiary referral centers within the framework of Yangtze River Delta of China. Their baseline data were reviewed, and follow-up clinical information were collected prospectively. Results: The mean age at onset was 37.3 (range 3-80 years) years and the female-to-male ratio was 8.1:1. The median disease duration was 47 months (interquartile range [IQR] 25-84 months). A total of 1372 attacks of the 502 patients were recorded till the last follow-up, with a median annualized relapse rate of 0.4 (IQR 0.3-0.6). Nearly one-fourth (24.5%, 336/1372) of the attacks had prodromic events, including upper respiratory tract infection (36.3%, 122/336), fever (20.2%, 68/336) and pregnancy-related issues (17.9%, 60/336), etc. Myelitis was the most common attack type throughout the disease course (51.4%, 705/1372), followed by optic neuritis (ON, 43.1%, 592/1372). As for onset phenotype, ON (37.3%, 187/502) prevailed over myelitis (28.3%, 142/ 502). The median time to first relapse was 12 months (IQR 5-25 months). Patients with brainstem encephalitis at onset were more likely to have other anatomical region involved in subsequent attacks (p < 0.001), compared to other onset type. The median serum AQP4-ab titer measured by cell-based assays was 1:100 (IQR 1:32-1:320, range 1:10-1:10,000). The baseline AQP4-ab titer in cerebrospinal fluid (r = 0.542, p < 0.001), overall ARR (r = 0.232, p < 0.001) and the EDSS scores at last follow-up (r = 0.119, p = 0.022) significantly correlated with baseline serum AQP4-ab titer. Antinuclear antibodies (48.4%), thyroid peroxidase antibodies (30.7%), and anti -SSA antibodies (26.2%) represented the most frequent concomitant antibodies, while autoimmune thyroid dis-orders (13.1%, 66/502) and Sjogren's syndrome (10.8%, 54/502) were the most common accompanying autoimmune diseases. Till the last follow-up, 403 patients received preventive treatments. Azathioprine represented the most common initial treatment, mycophenolate mofetil and rituximab was the most common second and third-line treatment, respectively. The EDSS score at the last follow-up ranged from 0 to 8.5 with a median of 2 (IQR 1-3). Conclusions: A comprehensive clinical picture of patients with AQP4-ab-positive NMOSD in Yangtze River Delta area of China was presented. More information on disease tragedy and predictive prognostic factors could be generated through long-term observations.

Neuromyelitis Optica Antibodies In Patients With Severe Optic Neuritis In China

A Retrospective Study of Ocular Manifestations and Aquaporin 4 Antibody Concentrations in 132 Patients with Neuromyelitis Optica

Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies

Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study

Serum Immunoglobulin G Level and Neutrophils to Lymphocytes Ratio Associated with the Prognosis of Neuromyelitis Optica Spectrum Disorder.

Clinical and diagnostic spectrum of optic neuritis: A single-center retrospective study of disorders associated with multiple sclerosis, anti-aquaporin-4 and anti-myelin oligodendrocyte glycoprotein antibodies

A Prospective Case-Control Study Comparing Optical Coherence Tomography Characteristics in Neuromyelitis Optica Spectrum Disorder- Optic Neuritis and Idiopathic Optic Neuritis

Structural and Functional Alterations in Visual Pathway After Optic Neuritis in MOG Antibody Disease: A Comparative Study With AQP4 Seropositive NMOSD

Clinical, Radiographic Characteristics and Immunomodulating Changes in Neuromyelitis Optica with Extensive Brain Lesions

Analysis of Clinical and Imaging Characteristics of NMOSDs Patients Based on the 2015 Version of Diagnostic Criteria

Clinical and Ocular Manifestation of Neuromyelitis Optica and Multiple Sclerosis

Neuromyelitis optica IgG and related clinical features of patients with neuromyelitis optica

Correlation between Aquaporin-4 Antibody and Optic Neuropathy in Patients with Neuromyelitis Optica Spectrum Disorder

[Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder]

Neuromyelitis optica: an overview

A comparative study on anti-MOG and anti-AQP4 associated optic neuritis following mild COVID-19: insights from a Chinese single-center experience

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features

Neurological Outcome and Predictive Factors of Idiopathic Optic Neuritis in China.

The Description of Neuromyelitis Optica Spectrum Disorder: Patient Registry in Yangtze River Delta Area of China.

[Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody]

Prevalence of serum MOG antibody and AQP4 antibody in optic neuritis after SARS-CoV-2 infection